S1226 Phase I Successfuly COMPLETED Q2 2014
We are pleased to share that the S1226 Phase I Successfuly COMPLETED. We are currently analyzing the data and writing up the study results for submission to Health Canada. We are very pleased with the results which encourage us to believe there are no serious safey issues associated with our S1226 asthma drug.
Prof Francis Green led the safety committee during this trial and he will update shareholders attending ourJune 12 SolAeroMed AGM.
John Dennis, CEO